Purple Biotech Reports Q3 2026 Results; Net Loss $1.0M on Lower Operating Expenses
Purple Biotech Ltd. reported a net loss of $1.0 million for Q3 2026, compared to a net loss of $1.3 million for Q3 2025, as operating expenses declined. Operating loss decreased to $1.1 million from $1.4 million, driven by lower R&D and G&A spending. The company ended Q3 2026 with $5.1 million in cash and cash equivalents, which management expects to fund operations through late-2027. The company also announced leadership transition with Isaac Israel appointed as Interim CEO following the departure of Gil Efron.
Read source-backed brief